This immunohistochemistry study, conducted in partnership with Charles River Laboratories Montreal ULC, represents a key step in the preclinical development of HT-KIT.
Development and optimization of staining methods for (c-Kit) markers, a critical target in HT-KIT therapeutic mechanism.
Processing and qualitative evaluation of tissue samples by a board-certified pathologist to determine the presence of markers.
Comprehensive reporting and insights to support the continued development of HT-KIT.
"This partnership is instrumental in our efforts to advance HT-KIT, a promising therapeutic aimed at targeting c-Kit in cancer treatments," said Robb Knie, CEO at Hoth Therapeutics. "We are committed to driving innovative solutions that can transform patient care."
The study aligns with Hoth Therapeutics' mission to accelerate groundbreaking therapies and address unmet medical needs in oncology.
About HT-KIT:
HT-KIT is Hoth's preclinical therapeutic candidate targeting c-Kit, a receptor tyrosine kinase involved in various cancers. This candidate represents a potential advancement in precision oncology therapies.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options.
For more, please visit https://ir.hoththerapeutics.com/
